Today

Agents

Chat

Arena

Discover

More

App

FDA Approves Celcuity's Gedatolisib for Advanced Breast Cancer - CELC News | Rallies

FDA Approves Celcuity's Gedatolisib for Advanced Breast Cancer

CELC•2026-07-14

FDA approves gedatolisib for advanced breast cancer

FDA: Approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

Related News

Alcoa takes final investment decision on gallium plant at Wagerup refinery in Western Australia

AA•2026-07-14

Australia, Japan, The United States And Alcoa Announce Final Investment Decision For Gallium Project In Western Australia

AA•2026-07-14

OpenAI's first hardware device will be a speaker, Bloomberg News reports

AAPL•2026-07-14

Celcuity Announces FDA Approval Of Revtorpyk™ (Gedatolisib) For The Treatment Of Hr+/Her2-, Pik3ca Wild-Type Locally Advanced Or Metastatic Breast Cancer

CELC•2026-07-14

Alignment Healthcare CEO John E. Kao disposes of common shares worth $5.92 million

ALHC•2026-07-14